IMGT CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,090 KRW | -2.42% |
|
-4.43% | +45.84% |
| 1 week | -4.43% | ||
| Current month | -23.87% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| 1 day | -2.42% | ||
| 1 week | -4.43% | ||
| Current month | -23.87% | ||
| 1 month | -41.88% | ||
| 3 months | +33.89% | ||
| 6 months | +70.52% | ||
| Current year | +45.84% |
1 week
11 980.00
13 090.00
1 month
10 820.0021 500.00
Current year
8 000.0026 500.00
1 year
5 900.0026 500.00
3 years
5 900.0026 500.00
5 years
5 900.0026 500.00
10 years
5 900.0026 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hak-Jong Lee
CEO | Chief Executive Officer | - | - |
IMGT Corp Ltd is a Korea-based company principally engaged in the drug delivery system development and sale business. The Company focus on researching and developing of ultrasound-guided therapy technology which utilizes ultrasound and nanoparticle technology. The Company provides IMGT-LPS, IMGT-EMB and IMGT-TSD technologies. IMGT-LPS technology injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into body and releases drugs by irradiating ultrasound to the target area. IMGT-EMB is a nanoparticle for chemoembolization of liver cancer and can be injected into cancer area in form of emulsion. IMGT-TSD is a targeted sonodynamic therapy induces immune boosting mechanism by applying ultrasonic stimulation to the cancer area. In addition, the Company engages in the non-invasive treatment devices IMGT-FUS which using focused ultrasound technology.
| 1st Jan change | Capi. | |
|---|---|---|
| +45.84% | 43.15M | |
| +29.03% | 48.16B | |
| -0.10% | 41.73B | |
| +43.45% | 41.03B | |
| -5.26% | 28.77B | |
| +11.48% | 25.59B | |
| -22.74% | 18.96B | |
| +9.06% | 12.92B | |
| +30.01% | 12.03B | |
| -1.51% | 11.77B |
- Stock Market
- Equities
- A456570 Stock